MA50505A - Anticorps 2 + 1 bispécifiques (contorsbodies) - Google Patents
Anticorps 2 + 1 bispécifiques (contorsbodies)Info
- Publication number
- MA50505A MA50505A MA050505A MA50505A MA50505A MA 50505 A MA50505 A MA 50505A MA 050505 A MA050505 A MA 050505A MA 50505 A MA50505 A MA 50505A MA 50505 A MA50505 A MA 50505A
- Authority
- MA
- Morocco
- Prior art keywords
- contorsbodies
- bispecific antibodies
- bispecific
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17199537 | 2017-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50505A true MA50505A (fr) | 2020-09-09 |
Family
ID=60201893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050505A MA50505A (fr) | 2017-11-01 | 2018-10-31 | Anticorps 2 + 1 bispécifiques (contorsbodies) |
Country Status (18)
Country | Link |
---|---|
US (1) | US20210324108A1 (fr) |
EP (1) | EP3703821A2 (fr) |
JP (1) | JP7098725B2 (fr) |
KR (1) | KR20200079492A (fr) |
CN (1) | CN111182944B (fr) |
AU (1) | AU2018357923A1 (fr) |
BR (1) | BR112020006443A2 (fr) |
CA (1) | CA3076027A1 (fr) |
CL (1) | CL2020000662A1 (fr) |
CR (1) | CR20200171A (fr) |
IL (1) | IL272747A (fr) |
MA (1) | MA50505A (fr) |
MX (1) | MX2020004571A (fr) |
PE (1) | PE20210844A1 (fr) |
SG (1) | SG11202002903XA (fr) |
TW (1) | TWI829658B (fr) |
WO (1) | WO2019086500A2 (fr) |
ZA (1) | ZA202001139B (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS61870B1 (sr) | 2014-11-14 | 2021-06-30 | Hoffmann La Roche | Antigen vezujući molekuli koji sadrže trimer liganda iz tnf familije |
JP6675017B2 (ja) * | 2016-05-02 | 2020-04-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | コントースボディ−単鎖標的結合物質 |
KR20190093588A (ko) | 2016-12-20 | 2019-08-09 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
EP3565843A1 (fr) | 2017-01-03 | 2019-11-13 | H. Hoffnabb-La Roche Ag | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb |
CN110573528B (zh) * | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 针对共刺激性tnf受体的双特异性抗原结合分子 |
WO2018178076A1 (fr) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Molécule bispécifique de liaison à l'antigène pour un récepteur de co-stimulation du tnf |
CN112955468A (zh) | 2018-10-01 | 2021-06-11 | 豪夫迈·罗氏有限公司 | 包含抗fap克隆212的双特异性抗原结合分子 |
US11608376B2 (en) | 2018-12-21 | 2023-03-21 | Hoffmann-La Roche Inc. | Tumor-targeted agonistic CD28 antigen binding molecules |
JP2022530034A (ja) * | 2019-04-25 | 2022-06-27 | エフ.ホフマン-ラ ロシュ アーゲー | 半減期が延長された活性化可能な治療用多重特異性ポリペプチド |
CA3132275A1 (fr) * | 2019-04-25 | 2020-10-29 | Ulrich Brinkmann | Generation de polypeptides derives d'anticorps par echange de chaines polypeptidiques |
CA3132494A1 (fr) * | 2019-04-25 | 2020-10-29 | Ulrich Brinkmann | Polypeptides therapeutiques multispecifiques actives par echange de chaines polypeptidiques |
US20220259328A1 (en) * | 2019-05-15 | 2022-08-18 | Kyowa Kirin Co., Ltd. | Bispecific antibody binding to cd40 and fap |
CN114531878A (zh) * | 2019-06-27 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 新颖icos抗体及包含它们的肿瘤靶向抗原结合分子 |
AR121706A1 (es) * | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
CR20220586A (es) * | 2020-05-19 | 2023-01-09 | Boehringer Ingelheim Int | Moléculas de fijación para el tratamiento de cáncer |
WO2023245022A2 (fr) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Agents de liaison multispécifiques qui ciblent b7h3 et gd2, et leurs utilisations |
WO2024038183A1 (fr) * | 2022-08-18 | 2024-02-22 | Immunocore Limited | Molécules de liaison à domaines multiples |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1156905B (it) | 1977-04-18 | 1987-02-04 | Hitachi Metals Ltd | Articolo di ornamento atto ad essere fissato mediante un magnete permanente |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP1997894B1 (fr) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Protéine de liaison biosynthétique pour un marqueur du cancer |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
WO1998058964A1 (fr) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Procedes et compositions concernant des glycoproteines galactosylees |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
WO1999022764A1 (fr) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Compositions renfermant des glycoformes de glycoproteine et methodes afferentes |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
EP2261229A3 (fr) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Modification par glycosylation d'anticorps aux fins d'amélioration de la cytotoxicité cellulaire dépendant des anticorps |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
EP1332209B1 (fr) | 2000-09-08 | 2009-11-11 | Universität Zürich | Groupes de proteines a domaines de repetition comprenant des modules de repetition |
EP1423510A4 (fr) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7993650B2 (en) | 2003-07-04 | 2011-08-09 | Affibody Ab | Polypeptides having binding affinity for HER2 |
WO2005019255A1 (fr) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteines de la lipocaline lacrymale |
CN1326881C (zh) * | 2003-09-29 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种三价双特异性抗体,其制备方法及用途 |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
HUE031632T2 (en) | 2003-11-05 | 2017-07-28 | Roche Glycart Ag | Antigen binding molecules with enhanced Fc receptor binding affinity and effector function |
SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
EP2360186B1 (fr) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anticorps dirigés contre la sélectine P |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP3623473A1 (fr) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble |
PL1885399T3 (pl) | 2005-05-26 | 2011-04-29 | Seattle Genetics Inc | Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania |
CA2646965C (fr) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Domaines de proteine heterodimerique d'ingenierie |
WO2007147901A1 (fr) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
EP1958957A1 (fr) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprenant un partie caractéristique des protéines appellées "Knottins" |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
EP2417156B1 (fr) * | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Anticorps trivalents, bispécifiques |
EP2424567B1 (fr) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Procédé de fabrication de molécules hétéromultimères |
EP2519544A1 (fr) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Hétérodimères polypeptidiques et leurs utilisations |
WO2011143545A1 (fr) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Protéines hétérodimériques et leurs procédés de production et de purification |
UA113712C2 (xx) * | 2010-08-13 | 2017-02-27 | Антитіло до fap і способи його застосування | |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
DK2691417T3 (en) | 2011-03-29 | 2018-11-19 | Roche Glycart Ag | ANTIBODY FC VARIANTS |
PT2794905T (pt) | 2011-12-20 | 2020-06-30 | Medimmune Llc | Polipéptidos modificados para estrutura de anticorpos bispecíficos |
AU2013249985B2 (en) | 2012-04-20 | 2017-11-23 | Merus N.V. | Methods and means for the production of Ig-like molecules |
EP2948475A2 (fr) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Procédés et compositions pour la modulation du systéme immunitaire |
AU2016329120B2 (en) | 2015-10-02 | 2023-04-13 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for a costimulatory TNF receptor |
CR20180171A (es) | 2015-10-07 | 2018-05-03 | Hoffmann La Roche | Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador |
JP7195929B2 (ja) * | 2016-04-13 | 2022-12-26 | サノフイ | 三重特異性および/または三価結合タンパク質 |
JP6675017B2 (ja) * | 2016-05-02 | 2020-04-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | コントースボディ−単鎖標的結合物質 |
EP3565843A1 (fr) * | 2017-01-03 | 2019-11-13 | H. Hoffnabb-La Roche Ag | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb |
JP6997209B2 (ja) * | 2017-04-04 | 2022-02-04 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Cd40およびfapに特異的に結合することができる新規な二重特異性抗原結合分子 |
-
2018
- 2018-10-31 TW TW107138691A patent/TWI829658B/zh active
- 2018-10-31 CN CN201880063441.2A patent/CN111182944B/zh active Active
- 2018-10-31 AU AU2018357923A patent/AU2018357923A1/en active Pending
- 2018-10-31 MA MA050505A patent/MA50505A/fr unknown
- 2018-10-31 EP EP18800546.6A patent/EP3703821A2/fr active Pending
- 2018-10-31 BR BR112020006443-2A patent/BR112020006443A2/pt unknown
- 2018-10-31 KR KR1020207011913A patent/KR20200079492A/ko not_active Application Discontinuation
- 2018-10-31 US US16/760,820 patent/US20210324108A1/en active Pending
- 2018-10-31 WO PCT/EP2018/079785 patent/WO2019086500A2/fr unknown
- 2018-10-31 MX MX2020004571A patent/MX2020004571A/es unknown
- 2018-10-31 JP JP2020523704A patent/JP7098725B2/ja active Active
- 2018-10-31 SG SG11202002903XA patent/SG11202002903XA/en unknown
- 2018-10-31 CA CA3076027A patent/CA3076027A1/fr active Pending
- 2018-10-31 CR CR20200171A patent/CR20200171A/es unknown
- 2018-10-31 PE PE2020000390A patent/PE20210844A1/es unknown
-
2020
- 2020-02-18 IL IL272747A patent/IL272747A/en unknown
- 2020-02-24 ZA ZA2020/01139A patent/ZA202001139B/en unknown
- 2020-03-13 CL CL2020000662A patent/CL2020000662A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20210324108A1 (en) | 2021-10-21 |
PE20210844A1 (es) | 2021-05-10 |
MX2020004571A (es) | 2020-08-24 |
CR20200171A (es) | 2020-06-14 |
TW201922791A (zh) | 2019-06-16 |
WO2019086500A2 (fr) | 2019-05-09 |
EP3703821A2 (fr) | 2020-09-09 |
JP7098725B2 (ja) | 2022-07-11 |
RU2020117441A (ru) | 2021-12-01 |
BR112020006443A2 (pt) | 2020-09-29 |
CL2020000662A1 (es) | 2020-10-02 |
CA3076027A1 (fr) | 2019-05-09 |
CN111182944A (zh) | 2020-05-19 |
KR20200079492A (ko) | 2020-07-03 |
WO2019086500A3 (fr) | 2019-08-29 |
AU2018357923A1 (en) | 2020-03-05 |
CN111182944B (zh) | 2022-11-22 |
IL272747A (en) | 2020-04-30 |
SG11202002903XA (en) | 2020-04-29 |
ZA202001139B (en) | 2021-03-31 |
RU2020117441A3 (fr) | 2022-04-01 |
TWI829658B (zh) | 2024-01-21 |
JP2021500898A (ja) | 2021-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
MA47694A (fr) | Anticorps anti-tigit | |
MA49034A (fr) | Anticorps anti-lag3 | |
MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
MA53434A (fr) | Anticorps anti-tigit | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA47268A (fr) | Anticorps anti-gpc3 | |
MA46057A (fr) | Anticorps anti-ctla4 | |
DK3735147T3 (da) | Rygsæk | |
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
MA45255A (fr) | Anticorps inhibiteurs de points de contrôle bispécifiques | |
MA46041A (fr) | Anticorps anti-tim -3 | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
MA53297A (fr) | Anticorps anti-icos | |
MA44381A (fr) | Format d'anticorps hétérodimères multispécifiques | |
MA50352A (fr) | Anticorps multispécifiques | |
MA49749A (fr) | Anticorps anti-cd137 | |
MA44054A (fr) | Plateforme d'anticorps bispécifique | |
DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
MA52366A (fr) | Anticorps anti-tl1a optimisés | |
MA53905A (fr) | Anticorps stabilisant trem2 | |
MA51134A (fr) | Anticorps anti-alpha-synucléine | |
MA52152A (fr) | Anticorps | |
MA42843A (fr) | Anticorps anti-cd115 |